anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a single-center prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before total knee arthroplasty (TKA). This study aims to recruit 110 patients across a single centre over 1 year. Eligible patients will be included in this study after signing the informed consent form. Before TKA, the patients will be randomly assigned to either a preemptive stepwise infiltration anaesthesia (PSIA) group or a postoperative local infiltration analgesia (PLIA) group and administered different pain management protocols during surgery. Clinical evaluation will be conducted at baseline, before surgery, and at 6, 12, 24, 48, and 72 hours postoperatively, as well as during follow-up visits at 3 weeks, 6 weeks and 6 months postoperatively. The primary outcomes are the amount of morphine consumed within 0-24 hours postsurgery and the visual analogue scale (VAS) score postsurgery. Secondary outcomes include the time to first rescue analgesia, total morphine consumption during hospitalization, postoperative joint function (measured by the Hospital for Special Surgery \[HSS\] score and knee joint range of motion \[ROM\]), intraoperative bleeding and serological indicators. All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the end of total knee arthroplasty and 6h, 12h, 24h, 48h, 72h, 3 weeks, 6 weeks and 6 months later, aimed at comparing the postoperative pain and inflammatory response between PSIA and PLIA, to explore the optimal perioperative analgesic modality for TKA. Statistical analyses utilizing regression models and survival analysis will be conducted to assess the relationships between the pain management method and postoperative pain and efficacy.
Endometriosis is defined as the presence of endometrial glands and stroma outside of the uterus, most commonly over the ovaries, fallopian tubes, bladder, recto-sigmoid colon and the uterine myometrium.Endometriosis affects 5%-15% of women in the reproductive age causing pelvic or abdominal pain, infertility and occasionally rectal bleeding (if involving the bowel). Deep endometriosis is mostly defined as a single endometrial nodule, usually larger than 1 cm which is located in the vesico-uterine fold or close to the distal 20 cm of the large bowel. Those lesions usually infiltrate at least 5 mm into the tissue involved. The gold standard of diagnosis is histological proven endometriosis, usually obtained during explorative laparoscopy. Other imaging tests that aid in the diagnosis are trans-vaginal or trans-rectal sonography (TRUS), MRI \& CT. Current guidelines recommends that laparoscopy with histology should be done to diagnose endometriosis. Negative (normal) laparoscopy is highly accurate in excluding endometriosis, but a positive laparoscopy (i.e. with macroscopic findings) without biopsy has a limited value. In practice, many clinicians refrain from taking biopsies due-to the risk of bowel surgery, particularly on an un-prepared bowel. Probe-based confocal laser endomicroscopy (pCLE) has been used as a GI tract endoscopy additive tool in recent years, providing in-vivo cellular-level imaging, a concept known as "optical biopsy". considering the rectal bleeding that occurs in patients suffering from bowel endometriosis, usually with a normal mucosa seen at standard endoscopy (personal data), we hypothesized that there might be histological architectural changes in the vessels or the mucosa/sub mucosa in bowel endometriosis.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are debilitating multisystemic conditions sharing similarities in immune dysregulation and cellular signaling pathways contributing to the pathophysiology. In this study, immune exhaustion gene expression was investigated in participants with ME/CFS or long COVID concurrently. RNA was extracted from peripheral blood mononuclear cells isolated from participants with ME/CFS (n = 14), participants with long COVID (n = 15), and healthy controls (n = 18). Participants with ME/CFS were included according to Canadian Consensus Criteria. Participants with long COVID were eligible according to the case definition for "Post COVID-19 Condition" published by the World Health Organization. RNA was analyzed using the NanoString nCounter Immune Exhaustion gene expression panel. Differential gene expression analysis in ME/CFS revealed downregulated IFN signaling and immunoglobulin genes, and this suggested a state of immune suppression. Pathway analysis implicated dysregulated macrophage activation, cytokine production, and immunodeficiency signaling. Long COVID samples exhibited dysregulated expression of genes regarding antigen presentation, cytokine signaling, and immune activation. Differentially expressed genes were associated with antigen presentation, B cell development, macrophage activation, and cytokine signaling. This investigation elucidates the intricate role of both adaptive and innate immune dysregulation underlying ME/CFS and long COVID, emphasizing the potential importance of immune exhaustion in disease progression.
PCT No. PCT/SE89/00707 Sec. 371 Date Apr. 25, 1991 Sec. 102(e) Date Apr. 25, 1991 PCT Filed Dec. 1, 1989 PCT Pub. No. WO90/06064 PCT Pub. Date Jun. 14, 1990.The present invention relates to a process for reducing the excretion of nitrogen from humans and animals while maintaining formation of proteins, as well as a food and feedstuff for humans and animals comprising keto acids, whereby ingoing protein is replaced by alpha ketoglutaric acid; a combination of alpha keto glutaric acid and pyruvic acid; oxaloacetate or oxaloacetate in combination with alpha keto glutaric acid or pyruvate or another keto acid according to the formula R-CO-COOX, wherein R denotes a part of a non-essential amino acid and X denotes hydrogen, alkali metal, alkaline earth metal or organic base or non-toxic precursors or intermediates of these, whereby the keto acid (-s) is (are) present in an amount of 1 to 20% by weight, preferably 1-10% by weight of the protein dry matter present.
Two-year inhalation studies in Sprague-Dawley rats and CD1 mice were conducted to assess the carcinogenic potential of revefenacin. No evidence of tumorigenicity was observed in male and female rats at inhaled doses up to 338 mcg/kg/day (approximately 35 times the MRHD based upon summed AUCs for revefenacin and its active metabolite). No evidence of tumorigenicity was observed in male and female mice at inhaled doses up to 326 mcg/kg/day (approximately 40 times the MRHD based on summed AUCs for revefenacin and its active metabolite).

Revefenacin and its active metabolite were negative for mutagenicity in the Ames test for bacterial gene mutation. Revefenacin was negative for genotoxicity in the in vitro mouse lymphoma assay and in vivo rat bone marrow micronucleus assay.

There were no effects on male or female fertility and reproductive performance in rats at subcutaneous revefenacin doses up to 500 mcg/kg/day (approximately 30 times the MRHD on an mg/m2 basis for revefenacin).
PURPOSE:To accelerate transition of bleomycin into a cancer cell, increase concentration and reinforce carcinostatic property by dissolving or dispersing bleomycin into a mixed micell comprising an unsaturated aliphatic glycerol monoester solubilized with a surfactant. CONSTITUTION:Bleomycin is dissolved or dispersed into a mixed micell preferably composed of >=14C long chain unsaturated aliphatic glycerol monoester (e.g. monolinolein) solubilized with a surfactant (e.g. caster oil hardened with polyoxyethylene) to improve carcinostatic property of the bleomycin. Mixing ratio of the above-mentioned monoester to bleomycin is preferably 1-1000 times mol and the mixed micell solution is prepared by performing ultrasonic wave treatment or homogenizing treatment, etc., to attain visibly transparent or translucent state. Improvement of effect by said mixed micell is expected to a drug other than bleomycin, too.
PURPOSE: Dyslipidemia plays a pivotal role in increasing cardiovascular risk. In clinical practice the misleading association between altered lipid profile and obesity is common, therefore genetically inherited dyslipidemias may not completely be addressed among patients with overweight. Thus, we aim to investigate the influence of overweight and obesity on the lipid phenotype in a cohort of patients with different forms of dyslipidemia.
METHODS: A retrospective analysis was conducted on patients with dyslipidemia from 2015 to 2022. Patients were stratified in familial hypercholesterolemia (FH), familial combined hyperlipidemia (FCHL), non-familial hyperlipidemia or polygenic hypercholesterolemia (PH). Clinical characteristics and lipid profile were evaluated.
RESULTS: Of the total of 798 patients, 361 were affected by non-familial hyperlipidemia (45.2%), while FCHL, FH and PH was described in 19.9%, 14.0% and 20.9% of patients, respectively. Overweight prevalence was higher in FCHL and non-familial hyperlipidemia patients than FH and PH patients. Subjects with overweight and obesity were independently associated with lower levels of high-density lipoprotein cholesterol (HDL-C) compared to patients with normal weight (52.4 and 46.0 vs 58.1, respectively; p < 0.0001); levels of triglycerides (TG) and non-HDL-C were higher in patients with overweight and obesity than patients with normal weight (257.3 and 290.9 vs 194.8, and 221.5 and 219.6 vs 210.1, p < 0.0001 and p = 0.01, respectively), while no differences were observed between patients with overweight and obesity.
CONCLUSION: While dyslipidemias can be influenced by various factors, an important determinant may lie in genetics, frequently acting as an underlying cause of altered lipid profiles, even in cases of overweight conditions.
Peripheral trigeminal neuropathies are assessed by MR neurography for presurgical mapping. In this clinical report, we aimed to understand the utility of MR neurography following nerve-repair procedures. We hypothesized that postoperative MR neurography assists in determining nerve integrity, and worsening MR neurography findings will corroborate poor patient outcomes. Ten patients with peripheral trigeminal neuropathy were retrospectively identified after nerve-repair procedures, with postsurgical MR neurography performed from July 2015 to September 2023. Postsurgical MR neurography findings were graded as per postintervention category and subcategories of the Neuropathy Score Reporting and Data System (NS-RADS). Descriptive statistics of demographics, inciting injury, injury severity, NS-RADS scoring, and clinical outcomes were obtained. There were 6 women and 4 men (age range, 25-73 years). Most injuries resulted from third molar removals (8/10), with an average time from the inciting event to nerve-repair surgery of 6.1 (SD, 4.6) months. In Neuropathy Score Reporting and Data System-Injury (NS-RADS I), NS-RADS I-4 injuries (neuroma in continuity) were found in 8/10 patients, and NS-RADS I-5 injuries were found in the remaining patients, all confirmed at surgery. Surgeries performed included microdissection with neurolysis, neuroma excision, and nerve allograft with Axoguard protection. Three patients with expected postsurgical MR neurography findings experienced either partial improvement or complete symptom resolution, while among 7 patient with persistent or recurrent neuropathy on postsurgical MR neurography, one demonstrated partial improvement of sensation, pain, and taste and one experienced only pain improvement; the remaining 5 patients demonstrated no improvement. Postsurgical MR neurography consistently coincided with clinical outcomes related to pain, sensation, and lip biting and speech challenges. Lip biting and speech challenges were most amenable to recovery, even with evidence of persistent nerve pathology on postsurgical MR neurography.
All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
Recent studies suggest that probiotic supplementation has the potential to restore gut microbiota homeostasis and reduce fatty liver. No studies have examined the effects of probiotic supplementation on the gut microbiome in obese Hispanic youth who are increased risk of type 2 diabetes and fatty liver. Therefore, the investigator proposes a double-blind randomized trial of probiotic supplementation in obese Hispanic youth in order to determine if probiotic supplementation results in alterations to the gut micro biome. The purpose of this study is to demonstrate through a proof-of-concept trial that probiotics have the potential to alter the gut microbiome and gut hormones. As a secondary aim the investigator will examine wether any changes in the gut microbiome are related to changes in liver fat, fibrosis, glycemia, or body weight. The study team will recruit 40 obese Hispanic youth (12 - 18 years of age who are greater than or equal to Tanner stage 4) from hospitals, clinics, and community centers. The studies primary outcome is alterations in the composition of the gut microbiome which will be examined through fecal and blood bacterial profiling (16S DNA targeted metagenomics), markers of gut permeability/bacterial translocation, and gut derived hormones involved with appetite regulation (GLP-1, peptide YY, ghrelin). Secondary outcomes include liver fat and liver fibrosis (MR elastography), total body fat (DEXA), visceral fat (MRI). Participants will be randomly assigned to 16 weeks of probiotics (3 packets/day of VSL#3) or matched placebo. The main effects of the intervention will be evaluated in a general linear model, with change in outcomes as the dependent variable and active intervention group as the independent variable. Covariates will include sex, BMI percentile, the baseline value of the outcome variable, as well as baseline factors found to differ among groups. Post hoc pairwise comparisons of the two groups will adjust for multiple comparisons using a Tukey correction.
The moderate formation of the fibrotic scar plays an important role in functional recovery after stroke. M2a macrophages have been identified as an important source of early fibrosis after cerebral ischemia. However, the underlying mechanisms by which macrophages interact with fibroblasts in this context remain largely unknown. Therefore, our study aimed to further investigate the potential mechanisms underlying the effects of macrophages on fibroblasts following ischemic stroke. In vitro and in vivo, recombinant rat interleukin 4 (IL4) was used to induce macrophages to polarize into M2a macrophages. In vitro, primary Sprague-Dawley newborn rat meningeal-derived fibroblasts were treated with PU.1 knockdown, the PU.1 inhibitor DB1976 or the mTOR inhibitor rapamycin, which were then co-cultured with M2a macrophage conditioned medium (MCM). In vivo, Sprague-Dawley adult rats were infected with negative control adenoviruses or PU.1-shRNA adenoviruses. Ten days after infection, an injury model of middle cerebral artery occlusion/reperfusion (MCAO/R) was constructed. Subsequently, IL4 was injected intracerebroventricularly to induce M2a macrophages polarization. In vitro, M2a MCM upregulated PU.1 expression and promoted the differentiation, proliferation, migration and extracellular matrix generation of fibroblasts, which could be reversed by treatment with the PU.1 inhibitor DB1976 or PU.1 knockdown. In vivo, PU.1 expression in fibroblasts was increased within ischemic core following MCAO/R, and this upregulation was further enhanced by exposure to IL4. Treatment with IL4 promoted fibrosis, increased angiogenesis, reduced apoptosis and infarct volume, as well as mitigated neurological deficits after MCAO/R, and these effects could be reversed by PU.1 knockdown. Furthermore, both in vivo and in vitro studies showed that IL4 treatment increased the levels of phosphorylated Akt and mTOR proteins, which were markedly decreased by PU.1 knockdown. Additionally, the use of an mTOR inhibitor rapamycin obviously suppressed the migration and differentiation of fibroblasts, and Col1 synthesis. In conclusion, our findings suggest for the first time that M2a macrophages, at least in part, regulate fibrosis and affect the outcome after cerebral ischemic stroke via the PU.1/mTOR signaling pathway in fibroblasts.
NEW MATERIAL:A fused polypeptide composed of a human colony-stimulating factor polypeptide and human interleukin-6 polypeptide. USE:An auxiliary therapeutic agent for recovery from the decrease of neutrophil of platelet in the therapy of cancer or in bone marrow transplantation. PREPARATION:For example, from a human thyroid gland-derived cell line NIM-1 (FERM P-11103) producing interleukin-6 and a colony-stimulating factor, the whole RNA is prepared by using the guanidium thiocyanate method. mRNA is separated by using an oligo-dT cellulose column and the cDNA library is formed thereby. A clone containing DNA coding interleukin-6 and the colony- stimulating factor respectively is selected therefrom by cloning and the respec tive exon parts of these DNA are mutually combined. The combined DNA is incorporated into a vector and intransduced into an eucaryotic cell to trans form the cell. The resultant transformed cell is cultured, thus obtaining the objective fused polypeptide.
Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
PROBLEM TO BE SOLVED: To produce a new compound having an indole ring and an oxazole ring, capable of manifesting physiological activities such as suppressing activities for lipid peroxidation and useful as a prophylactic and a therapeutic agents, etc., for disorders in circulatory organs such as arteriosclerosis, hypertension or thrombosis, inflammation such as nephritis, hepatopathy, etc., such as alcoholic hepatitis. SOLUTION: This compound is represented by formula I (R is H, an alkyl or the like), e.g. a compound represented by formula II (Ph is phenyl). The compound represented by formula I is preferably produced by condensing a tryptophan represented by formula III (e.g. L-tryptophan benzyl ester hydrochloride) with 4-methylhexanoic acid represented by formula IV and then carrying out the oxidative cyclizing reaction of the resultant amide derivative, preferably in the presence of 2,3-dichloro-5,6-dicyanobenzoquinone). The new compound is useful as a prophylactic agent for ultraviolet ray disturbance in a cosmetic material, etc.
The efficacy of HYCAMTIN for injection was evaluated in 426 patients with recurrent or progressive small cell lung cancer (SCLC) in a randomized, comparative trial and in 3 single-arm trials.

Randomized Comparative Trial

In a randomized, comparative trial, 211 patients were randomized 1:1 to receive HYCAMTIN for injection (1.5 mg/m2 once daily intravenously for 5 days starting on Day 1 of a 21-day cycle) or CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 mg/m2, vincristine 2 mg administered sequentially on Day 1 of a 21-day cycle). All patients were considered sensitive to first-line chemotherapy (responders who then subsequently progressed greater than or equal to 60 days after completion of first-line therapy). A total of 77% of patients treated with HYCAMTIN for injection and 79% of patients treated with CAV received platinum/etoposide with or without other agents as first-line chemotherapy. The efficacy outcome measures were overall response rate, response duration, time to progression or OS.

The results of the trial did not show statistically significant improvements in response rate, response duration, time to progression, or OS as shown in Table 5.

The median time to response was similar in both arms: HYCAMTIN, 6 weeks (2.4 weeks to 3.6 months) versus CAV, 6 weeks (5.1 weeks to 4.2 months).

Changes on a disease-related symptom scale are presented in Table 6. It should be noted that not all patients had all symptoms, nor did all patients respond to all questions. Each symptom was rated on a 4-category scale with an improvement defined as a change in 1 category from baseline sustained over 2 courses. Limitations in interpretation of the rating scale and responses preclude formal statistical analysis.

Single-Arm Trials

HYCAMTIN for injection was also studied in three open-label, non-comparative trials (Studies 014, 092 and 053) in a total of 319 patients with recurrent or progressive SCLC after treatment with first-line chemotherapy. In all three trials, patients were stratified as either sensitive (responders who then subsequently progressed greater than or equal to 90 days after completion of first-line therapy) or refractory (no response to first-line chemotherapy or who responded to first-line therapy and then progressed within 90 days of completing first-line therapy). Response rates ranged from 11% to 31% for sensitive patients and 2% to 7% for refractory patients. Median time to progression and median survival were similar in all three trials and the comparative trial.
PURPOSE: To provide a new compd. which forms bones of mammals or increases the bone mass and which is useful for the treatment for diseases with consumption of bones including postmenopausal osteoporosis.  
     CONSTITUTION: A compd. expressed by formula I or its pharmaceutically acceptable salts are provided. In the formula I, R 1 , R 2  are H, an alkyl, etc.; R 3 , R 5  are H, CF 3 , but only one of these is CF 3  at one time; R 4 , R 6  are H, CF 3 , however, when either or both of R 4 , R 6  are CF 3 , R 3  and R 5  are H, and it is not allowed that all of R 3  to R 6  are H, and when R 4 , R 6  are CF 3 , both of R 1 , R 2  may be ethyl. The compd. is, for example, allylethyl 3- trifluoromethylbenzylphosphonate. The compd. of the formula I is obtd., for example, by allowing a compd. expressed by formula II (X is chloro or bromo) to react with a trialkyl phosphite at 50 to 200°C to obtain a compd. expressed by formula III, then allowing the compd. of formula III to react with KOH to obtain a monoacid product expressed by formula IV, then converting the product into acid chloride, and then allowing the acid chloride to react with an alcohol. 
     COPYRIGHT: (C)1993,JPO
PURPOSE:To provide the titled drug preparation containing a cyclodextrin clathrate compound including acetylsalicylic acid and basic amino acid and/or basic amino acid salt of acetylsalicylic acid and having improved rapid action and durability of the principal drug. CONSTITUTION:The objective drug preparation contains a cyclodextrin (e.g. alpha-cyclodextrin) clathrate compound including acetylsalicylic acid and a basic amino acid (e.g. arginine) and/or a basic amino acid salt of acetylsalicylic acid. Although acetylsalicylic acid has been generally used as an antipyretic analgesic agent, it has only transient action and is liable to cause gastric disorder. The drug action of acetylsalicylic acid can be developed quickly over a long period and the stability of acetylsalicylic acid can be improved by using a clathrate compound of acetylsalicylic acid. The mechanism is not yet cleared. The amount of cyclodextrin is 0.1-2 times weight of the basic amino acid salt of acetylsalicylic acid.
PURPOSE:To provide a new antiulcerous agent containing, as active ingredient, marmin. CONSTITUTION:The objective antiulcerous agent containing, as active ingredient, marmin of the formula. This agent can be obtained by pharmaceutical manufacturing for marmin by a conventional method, or by pharmaceutical manufacturing in a similar way for the extract fraction from a R-(+)-marmin-contg. crude drug (e.g. quince, chinquapin). This antiulcerous agent is pref. perorally administered to man, its amount to be administered being normally pref. at 0.4-40mg/kg a day per adult at a time or in two to three portions.